Atea Pharmaceuticals (AVIR)
Develops oral antiviral candidates for HCV and HEV infections.
Something off on this page? Send us feedback.
Develops oral antivirals for serious viral diseases, with a late-stage HCV regimen and an early HEV candidate. The business is pre-commercial, concentrated in one antiviral therapeutics segment, and depends on clinical progress against established HCV direct-acting antivirals.
Builds orally administered antiviral candidates for serious viral diseases rather than marketed medicines. The current pipeline centers on bemnifosbuvir plus ruzasvir for chronic HCV, with AT-587 extending the same antiviral platform toward chronic HEV in immunocompromised patients.
Runs as one reportable antiviral therapeutics segment from Boston, with development activity split between North America and international HCV studies. Founder-CEO Jean-Pierre Sommadossi anchors the scientific and operating narrative, and the organization remains weighted toward research and development.
Commercial infrastructure has not yet been built out. The business depends on successful late-stage HCV readouts, regulatory review, access to the licensed ruzasvir component, and differentiation against approved direct-acting antiviral regimens.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 13, 2026 | Morgan Stanley | Reiterate | Equal Weight | $6.88 | $7 |
| Mar 9, 2026 | Evercore ISI | Target | $10 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $219.5M · Total debt $424.0K · Total assets $232.3M · Shareholders' equity $204.2M
- Revenue
- $0
- Operating income
- −$35.1M
- Net income
- −$32.9M
No dividends on record.
| Institutions127 holders · as of Jun 30, 2026 | 75.74% | 60.74M shares | |
| Insiders13 holders · as of Jun 23, 2026 | 10.84% | 8.70M shares | |
| Otherremainder | 13.42% | 10.76M shares |
80.20M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
FMR LLCInstitution | 14.97% | 12.00M | 13Fas of Jun 30, 2026 |
BlackRock, Inc.Institution | 10.87% | 8.72M | 13Fas of Jun 30, 2026 |
BML Investment Partners, L.P.Institution | 9.34% | 7.49M | 13Gfiled Feb 9, 2026 ↗ |
BML Capital Management, LLCInstitution | 8.67% | 6.95M | 13Fas of Jun 30, 2026 |
Jean-Pierre Sommadossi1Insiderdirector, officer: President, CEO, and Chairman | 7.90% | 5.87M | 13Gfiled Feb 3, 2026 ↗ |
| See all 25 → | |||
- Jean-Pierre Sommadossi's transaction reports restate only vehicles that traded; the 2025 ownership statement (5.87M) plus the 466.9K net shares acquired since is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 18, 2026 | Polly A. Murphy | director | +6,100 | $4.17 |
| May 18, 2025 | Polly A. Murphy | director | +6,100 | $4.17 |
- Gilead Sciences
Dominant HCV regimen owner and Phase 3 comparator benchmark
- AbbVie
Eight-week pangenotypic HCV regimen rival
- Merck
Genotype-focused HCV regimen rival
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Atea Pharmaceuticals | $5.73 | +0.44% | $456.2M | — | — | — | — |
| Gilead Sciences | $149.20 | −0.27% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| AbbVie | $261.07 | −0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Merck | $151.84 | +0.13% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Median | 97.5 | 17.2 | 6.1 | +10.2% |